Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for CNS diseases, with leading candidates roluperidone for schizophrenia and MIN-301 for Parkinson's. Established in 2014, the company also advances seltorexant for insomnia and MDD while employing nine full-time staff.
NERV filed a patent for "(2s)-1-[4-(3,4-dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy] propan-2-ol or its metabolite for treating anxiety disorders" on Tue, April 18, 2023. The patent was officially published on Thu, August 10, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
